Introduction

Bacterial vaginosis (BV) describes an overgrowth of predominately anaerobic organisms such as Gardnerella vaginalis. This leads to a consequent fall in lactic acid producing aerobic lactobacilli resulting in a raised vaginal pH.

Whilst BV is not a sexually transmitted infection it is seen almost exclusively in sexually active women.

Epidemiology

  • Incidence: 5000.00 cases per 100,000 person-years
  • Peak incidence: 20-30 years
Condition Relative
incidence
Bacterial vaginosis1
Vaginal candidiasis0.80
Trichomonas vaginalis0.20
Atrophic vaginitis0.20
<1 1-5 6+ 16+ 30+ 40+ 50+ 60+ 70+ 80+

Clinical features

Features

Diagnosis

Amsel's criteria for diagnosis of BV - 3 of the following 4 points should be present
  • thin, white homogenous discharge
  • clue cells on microscopy: stippled vaginal epithelial cells
  • vaginal pH > 4.5
  • positive whiff test (addition of potassium hydroxide results in fishy odour)

Differential diagnosis

Comparison of bacterial vaginosis and Trichomonas vaginalis

Management

Management
  • oral metronidazole for 5-7 days
  • 70-80% initial cure rate
  • relapse rate > 50% within 3 months
  • the BNF suggests topical metronidazole or topical clindamycin as alternatives

Bacterial vaginosis in pregnancy
  • results in an increased risk of preterm labour, low birth weight and chorioamnionitis, late miscarriage
  • it was previously taught that oral metronidazole should be avoided in the first trimester and topical clindamycin used instead. Recent guidelines however recommend that oral metronidazole is used throughout pregnancy. The BNF still advises against the use of high dose metronidazole regimes